Neuroscience-focused biopharmaceutical company Neurocrine Biosciences (Nasdaq:NBIX) on Thursday introduced INGREZZA SPRINKLE (valbenazine), a new sprinkle formulation of its treatment for tardive dyskinesia and chorea associated with Huntington's disease.

INGREZZA SPRINKLE provides an easier administration option for patients with swallowing difficulties, a common challenge for this patient group. The sprinkle capsules come in three dosages (40mg, 60mg, 80mg) and are designed to be easily opened with the contents sprinkled on soft food, such as applesauce, yogurt or pudding, for oral administration.

Neurocrine Biosciences received US Food and Drug Administration (FDA) approval for INGREZZA SPRINKLE in April 2024.